Mutations in oncogenes and tumor suppressor genes in animal and human tumors may give important clues as to the exposures that led to the tumors. For rodent neoplasms that are pathologically similar to the corresponding human cancer, the rodent disease may be used to model the cellular events involved and to study prevention and therapy. Currently, we are focusing on the von Hippel-Lindau ( VHL) gene in kidney cancer, and the K- ras gene in lung cancer. The VHL tumor suppressor gene is mutated in a high percentage of both familial and sporadic renal cell carcinomas. We have recently established an animal model for causation of VHL mutations in clear cell renal tumors, by the environmental carcinogen N-nitrosodimethylamine. In addition, we have found that VHL is down-regulated in several other types of kidney cancer in animal models. Investigation of the effects of altered VHL amounts or activities is currently involving microarrays, and transfection of the gene into kidney cells. In studies of the role of the oncogene K- ras in genesis of adenocarcinoma of the lung, we are utilizing a mouse model, including tumors induced in vivo, and normal immortalized and transformed alveolar type 2 cells in vitro. We are pursuing several novel hypotheses: that K- ras is actually a tumor suppressor gene, controlling growth and/or differentiation; that mutant K-ras generates reactive oxygen which leads to tumor initiation; and that N-ras may have a role in cell proliferation in lung cells. Failure of p53-dependent cell cycle arrest after carcinogen exposure is also under investigation.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC005399-17
Application #
6433023
Study Section
(LCC)
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Sithanandam, Gunamani; Fornwald, Laura W; Fields, Janet R et al. (2012) Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts. Int J Cancer 130:251-8
Sithanandam, G; Anderson, L M (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15:413-48
Romanowska, Malgorzata; Kikawa, Keith D; Fields, Janet R et al. (2007) Effects of selenium supplementation on expression of glutathione peroxidase isoforms in cultured human lung adenocarcinoma cell lines. Lung Cancer 55:35-42
Sithanandam, Gunamani; Smith, George T; Fields, Janet R et al. (2005) Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1. Am J Respir Cell Mol Biol 33:490-9
Sithanandam, Gunamani; Fornwald, Laura W; Fields, Janet et al. (2005) Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 24:1847-59
Anderson, Lucy M (2005) Cancer biology and hormesis: comments on Calabrese (2005). Crit Rev Toxicol 35:583-6
Maciag, Anna; Anderson, Lucy M (2005) Reactive oxygen species and lung tumorigenesis by mutant K-ras: a working hypothesis. Exp Lung Res 31:83-104
Vucenik, Ivana; Ramakrishna, Gayatri; Tantivejkul, Kwanchanit et al. (2005) Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation. Breast Cancer Res Treat 91:35-45
Dennis, Phillip A; Van Waes, Carter; Gutkind, J Silvio et al. (2005) The biology of tobacco and nicotine: bench to bedside. Cancer Epidemiol Biomarkers Prev 14:764-7
Maciag, Anna; Sithanandam, Gunamani; Anderson, Lucy M (2004) Mutant K-rasV12 increases COX-2, peroxides and DNA damage in lung cells. Carcinogenesis 25:2231-7

Showing the most recent 10 out of 13 publications